Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The role of ERT/HRT.

Göran Samsioe1

  • 1Department of Obstetrics and Gynaecology, Lund University Hospital, Sweden.

Best Practice & Research. Clinical Obstetrics & Gynaecology
|July 9, 2002
PubMed
Summary

Hormone replacement therapy (HRT) offers options for managing menopausal symptoms and bone health, with different regimens tailored to individual needs and health conditions. Careful consideration of estrogen, progestogen, tibolone, and raloxifene is crucial for optimal patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary screening for increased fracture risk by the FRAX® questionnaire-uptake rates in relation to invitation method.

Archives of osteoporosis·2019
Same author

EMAS position statement: The ten point guide to the integral management of menopausal health.

Maturitas·2015
Same author

Associations between cadmium exposure and circulating levels of sex hormones in postmenopausal women.

Environmental research·2014
Same author

Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.

Maturitas·2014
Same author

Alcohol use and early mortality in Swedish middle-aged women: Nine-year follow-up of the Women's Health in Lund Area study.

Scandinavian journal of public health·2014
Same author

To pick, choose, or single out.

Menopause (New York, N.Y.)·2013

Area of Science:

  • Reproductive Endocrinology
  • Geriatric Medicine
  • Pharmacology

Background:

  • The aging female population necessitates attention to gonadal hormone deficiency and its associated health issues.
  • Hormone replacement therapy (HRT) is a viable option for alleviating menopausal symptoms, requiring broader physician awareness beyond gynecology.

Purpose of the Study:

  • To outline appropriate hormone replacement therapy (HRT) strategies for women experiencing menopausal symptoms and hormone deficiencies.
  • To differentiate therapeutic approaches based on menopausal stage, hysterectomy status, and co-existing medical conditions.
  • To compare the benefits and risks of various HRT options, including estrogen, progestogen, tibolone, and selective estrogen receptor modulators (SERMs).

Main Methods:

  • Review of current therapeutic guidelines for hormone replacement therapy (HRT).
  • Analysis of different HRT formulations (oral, transdermal) and their suitability for specific patient profiles.
  • Comparison of HRT with alternative treatments like tibolone and raloxifene (SERM) for menopausal symptom management and bone health.

Main Results:

  • Estrogen monotherapy is restricted to women post-hysterectomy or for localized urogenital symptoms; otherwise, estrogen-progestogen combinations are necessary.
  • Therapeutic regimens vary from cyclical to sequential to continuous combined therapy based on menopausal progression and patient preference regarding bleeding.
  • Non-oral HRT is preferred for women with comorbidities like migraine or liver disease, while oral HRT may benefit those with specific lipid profiles.
  • Tibolone and raloxifene offer alternatives for osteoporosis prevention and management, with raloxifene showing a reduction in breast cancer incidence.

Conclusions:

  • Personalized HRT selection is critical, considering symptom severity, menopausal duration, route of administration, and individual health status.
  • Selective estrogen receptor modulators (SERMs) like raloxifene present a distinct option, particularly for breast cancer risk reduction.
  • Further research is needed to clarify the long-term effects of tibolone on breast cancer incidence.

Related Experiment Videos